Hello and welcome to the Intelligence on Economist Radio. I'm your host, Jason Palmer.

Every weekday we provide a fresh perspective on the events shaping your world.

What seems like a long time ago, the phrase working from home, suggested an easy day.

Now hundreds of millions of people know better. We look at the possible long-term impacts

for workers, for commercial property, maybe even for the makeup of cities.

And in Hong Kong, a straightforward history exam question has ignited an almighty fight.

As tensions imposed by Beijing rise, even high school essays can be seen as political acts,

and many of the kids aren't all right with it.

But first…

It wasn't so long ago that America's Republicans and Democrats found a rare area of agreement.

Drug prices were too high, and big pharmaceutical companies were to blame.

One of my greatest priorities is to reduce the price of prescription drugs.

It comes to prescription drugs. We're going to throw the book at the pharmaceutical companies in a huge repoll.

But the pandemic has led to a shift.

Yesterday, Novavax, an American biotech firm, said it had started the first human trial of its

coronavirus vaccine candidate. A few days after a small vaccine trial by Moderna,

another biotech company showed positive results. Last week, AstraZeneca said it had capacity

to manufacture a billion doses of a vaccine that's being developed by Oxford University.

And the firm has two drug candidates, it's testing that may help treat some of the worst

symptoms of COVID-19. As the world anxiously awaits both treatments and an eventual vaccine,

the industry's reputation has turned around.

Before the crisis, Big Pharma was an industry that had lost its way.

...